BJDX
Bluejay Diagnostics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$2.41
+9.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 249.0K |
| Cost of Revenue | 98.4K | — | — | — | 200.1K |
| Gross Profit | (98.4K) | — | — | — | 48.9K |
| Operating Expenses | |||||
| R&D Expense | 3.6M | 3.0M | 3.5M | 5.7M | 4.2M |
| SG&A Expense | 3.7M | 3.9M | 3.7M | 4.6M | 5.2M |
| General & Admin Expense | 3.7M | 3.9M | 3.7M | 4.3M | 4.8M |
| Selling & Marketing Expense | — | — | 8.3K | 283.4K | 451.4K |
| Other Expenses | (98.4K) | — | — | — | — |
| Total Operating Expenses | 7.3M | 7.0M | 7.2M | 10.3M | 9.4M |
| Cost and Expenses | 7.4M | 7.0M | 7.2M | 10.3M | 9.6M |
| Operating Income (EBIT) | (7.4M) | (7.0M) | (7.2M) | (10.3M) | (9.3M) |
| Non-Operating | |||||
| Interest Income | 94.2K | 97.6K | 145.8K | 164.9K | 89.7K |
| Interest Expense | 387.00 | 839.00 | 823.0K | — | — |
| Net Interest Income | 93.8K | 96.7K | (677.2K) | 164.9K | 89.7K |
| Other Non-Op Income/Expense | 93.1K | 104.5K | (548.2K) | 357.3K | 20.8K |
| Non-Operating Income (excl Interest) | (93.5K) | (105.3K) | (274.9K) | (357.3K) | (20.8K) |
| EBT (Pre-Tax Income) | (7.3M) | (6.8M) | (7.7M) | (10.0M) | (9.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.3M) | (6.8M) | (7.7M) | (10.0M) | (9.3M) |
| Earnings from Cont. Ops | (7.3M) | (6.8M) | (7.7M) | (10.0M) | (9.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.3M) | (6.8M) | (20.9M) | (10.0M) | (9.3M) |
| Per Share | |||||
| Basic EPS | ($37.92) | ($61.00) | ($1,827.04) | ($1,161.92) | ($1,171.52) |
| Diluted EPS | ($37.92) | ($61.00) | ($1,827.04) | ($1,161.92) | ($1,171.52) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $31.62 |
| Shares | |||||
| Basic Shares Outstanding | 519816 | 112261 | 11462 | 8567 | 7877 |
| Diluted Shares Outstanding | 519816 | 112261 | 11462 | 8567 | 7877 |
| Profitability Metrics | |||||
| EBITDA | (7.1M) | (6.7M) | (6.7M) | (9.2M) | (9.0M) |
| D&A | 180.4K | 170.7K | 199.1K | 781.0K | 306.4K |
| EBIT | (7.3M) | (6.8M) | (6.9M) | (10.0M) | (9.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026